DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES
The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | CHU, YU-WAYE WANG, HONG SIMKO, STEPHEN JAMES III TOTPAL, KLARA WEI, MICHAEL C YIN, SHEN BENDER, BRENDAN CHRISTIAN CHEN, XI LI, CHIUNG TO, IRIS TRANTHUYNGAN HRISTOPOULOS, MARIA O'HEAR, CAROL ELAINE |
| description | The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
La présente invention concerne le traitement de sujets ayant des troubles prolifératifs cellulaires CD20-positifs (par ex., des troubles prolifératifs des lymphocytes B, tels que les lymphomes non hodgkiniens). Plus spécifiquement, l'invention concerne le traitement de sujets ayant un trouble prolifératif cellulaire CD20-positifs (par ex., un trouble prolifératif des lymphocytes B) par administration d'une combinaison d'un anticorps bispécifique anti-CD20/anti-CD3 et d'un conjugué anticorps anti-CD79b-médicament. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3196191A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3196191A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3196191A13</originalsourceid><addsrcrecordid>eNqNikEKwjAQAHPxIOof9gNFY0HJMU227QomkmwRT6VIPIhoof4fRdq7pxmYmYu79ZFcBaUPwAE1H9ExnIlr0I4pM3a7WY-WQ0HxhIZKMr9aeEsYv2qnea-KqVzAhqYC492hqTRjXIrZrXsMaTVyIaBENnWW-lebhr67pmd6t0bnUu2kklrmfywftl006Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES</title><source>esp@cenet</source><creator>CHU, YU-WAYE ; WANG, HONG ; SIMKO, STEPHEN JAMES III ; TOTPAL, KLARA ; WEI, MICHAEL C ; YIN, SHEN ; BENDER, BRENDAN CHRISTIAN ; CHEN, XI ; LI, CHIUNG ; TO, IRIS TRANTHUYNGAN ; HRISTOPOULOS, MARIA ; O'HEAR, CAROL ELAINE</creator><creatorcontrib>CHU, YU-WAYE ; WANG, HONG ; SIMKO, STEPHEN JAMES III ; TOTPAL, KLARA ; WEI, MICHAEL C ; YIN, SHEN ; BENDER, BRENDAN CHRISTIAN ; CHEN, XI ; LI, CHIUNG ; TO, IRIS TRANTHUYNGAN ; HRISTOPOULOS, MARIA ; O'HEAR, CAROL ELAINE</creatorcontrib><description>The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
La présente invention concerne le traitement de sujets ayant des troubles prolifératifs cellulaires CD20-positifs (par ex., des troubles prolifératifs des lymphocytes B, tels que les lymphomes non hodgkiniens). Plus spécifiquement, l'invention concerne le traitement de sujets ayant un trouble prolifératif cellulaire CD20-positifs (par ex., un trouble prolifératif des lymphocytes B) par administration d'une combinaison d'un anticorps bispécifique anti-CD20/anti-CD3 et d'un conjugué anticorps anti-CD79b-médicament.</description><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220512&DB=EPODOC&CC=CA&NR=3196191A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220512&DB=EPODOC&CC=CA&NR=3196191A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CHU, YU-WAYE</creatorcontrib><creatorcontrib>WANG, HONG</creatorcontrib><creatorcontrib>SIMKO, STEPHEN JAMES III</creatorcontrib><creatorcontrib>TOTPAL, KLARA</creatorcontrib><creatorcontrib>WEI, MICHAEL C</creatorcontrib><creatorcontrib>YIN, SHEN</creatorcontrib><creatorcontrib>BENDER, BRENDAN CHRISTIAN</creatorcontrib><creatorcontrib>CHEN, XI</creatorcontrib><creatorcontrib>LI, CHIUNG</creatorcontrib><creatorcontrib>TO, IRIS TRANTHUYNGAN</creatorcontrib><creatorcontrib>HRISTOPOULOS, MARIA</creatorcontrib><creatorcontrib>O'HEAR, CAROL ELAINE</creatorcontrib><title>DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES</title><description>The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
La présente invention concerne le traitement de sujets ayant des troubles prolifératifs cellulaires CD20-positifs (par ex., des troubles prolifératifs des lymphocytes B, tels que les lymphomes non hodgkiniens). Plus spécifiquement, l'invention concerne le traitement de sujets ayant un trouble prolifératif cellulaire CD20-positifs (par ex., un trouble prolifératif des lymphocytes B) par administration d'une combinaison d'un anticorps bispécifique anti-CD20/anti-CD3 et d'un conjugué anticorps anti-CD79b-médicament.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNikEKwjAQAHPxIOof9gNFY0HJMU227QomkmwRT6VIPIhoof4fRdq7pxmYmYu79ZFcBaUPwAE1H9ExnIlr0I4pM3a7WY-WQ0HxhIZKMr9aeEsYv2qnea-KqVzAhqYC492hqTRjXIrZrXsMaTVyIaBENnWW-lebhr67pmd6t0bnUu2kklrmfywftl006Q</recordid><startdate>20220512</startdate><enddate>20220512</enddate><creator>CHU, YU-WAYE</creator><creator>WANG, HONG</creator><creator>SIMKO, STEPHEN JAMES III</creator><creator>TOTPAL, KLARA</creator><creator>WEI, MICHAEL C</creator><creator>YIN, SHEN</creator><creator>BENDER, BRENDAN CHRISTIAN</creator><creator>CHEN, XI</creator><creator>LI, CHIUNG</creator><creator>TO, IRIS TRANTHUYNGAN</creator><creator>HRISTOPOULOS, MARIA</creator><creator>O'HEAR, CAROL ELAINE</creator><scope>EVB</scope></search><sort><creationdate>20220512</creationdate><title>DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES</title><author>CHU, YU-WAYE ; WANG, HONG ; SIMKO, STEPHEN JAMES III ; TOTPAL, KLARA ; WEI, MICHAEL C ; YIN, SHEN ; BENDER, BRENDAN CHRISTIAN ; CHEN, XI ; LI, CHIUNG ; TO, IRIS TRANTHUYNGAN ; HRISTOPOULOS, MARIA ; O'HEAR, CAROL ELAINE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3196191A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>CHU, YU-WAYE</creatorcontrib><creatorcontrib>WANG, HONG</creatorcontrib><creatorcontrib>SIMKO, STEPHEN JAMES III</creatorcontrib><creatorcontrib>TOTPAL, KLARA</creatorcontrib><creatorcontrib>WEI, MICHAEL C</creatorcontrib><creatorcontrib>YIN, SHEN</creatorcontrib><creatorcontrib>BENDER, BRENDAN CHRISTIAN</creatorcontrib><creatorcontrib>CHEN, XI</creatorcontrib><creatorcontrib>LI, CHIUNG</creatorcontrib><creatorcontrib>TO, IRIS TRANTHUYNGAN</creatorcontrib><creatorcontrib>HRISTOPOULOS, MARIA</creatorcontrib><creatorcontrib>O'HEAR, CAROL ELAINE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CHU, YU-WAYE</au><au>WANG, HONG</au><au>SIMKO, STEPHEN JAMES III</au><au>TOTPAL, KLARA</au><au>WEI, MICHAEL C</au><au>YIN, SHEN</au><au>BENDER, BRENDAN CHRISTIAN</au><au>CHEN, XI</au><au>LI, CHIUNG</au><au>TO, IRIS TRANTHUYNGAN</au><au>HRISTOPOULOS, MARIA</au><au>O'HEAR, CAROL ELAINE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES</title><date>2022-05-12</date><risdate>2022</risdate><abstract>The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
La présente invention concerne le traitement de sujets ayant des troubles prolifératifs cellulaires CD20-positifs (par ex., des troubles prolifératifs des lymphocytes B, tels que les lymphomes non hodgkiniens). Plus spécifiquement, l'invention concerne le traitement de sujets ayant un trouble prolifératif cellulaire CD20-positifs (par ex., un trouble prolifératif des lymphocytes B) par administration d'une combinaison d'un anticorps bispécifique anti-CD20/anti-CD3 et d'un conjugué anticorps anti-CD79b-médicament.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3196191A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A52%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CHU,%20YU-WAYE&rft.date=2022-05-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3196191A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |